<DOC>
	<DOCNO>NCT00784784</DOCNO>
	<brief_summary>This unblinded pilot study intend assess feasibility large double-blind , randomize control trial . For large trial investigator interested understanding relative benefit vaccine antiviral prophylaxis , risk factor influenza infection healthy adult , assess safety tolerability seasonal antiviral prophylaxis healthcare worker . The pilot study assess rate infection influenza rate adherence long-term zanamivir 60 healthy volunteer .</brief_summary>
	<brief_title>Zanamivir Versus Trivalent Split Virus Influenza Vaccine</brief_title>
	<detailed_description>Several study demonstrate zanamivir oseltamivir effective prevent influenza infection illness use either prophylaxis exposure household contact influenza take several week height influenza activity general community . However , long duration prophylaxis neuraminidase inhibitor two clinical trial , date , six week . Antiviral medication likely important role response next influenza pandemic . Additionally , may indications use season major infect strain influenza one whose antigen well covered vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>1869 year old 01/Nov/2008 understanding study , agree provision , give write informed consent prior study entry available followup study period woman childbearing year , must meet criterion prevent pregnancy allergy component influenza vaccine zanamivir previous serious adverse event associate influenza vaccination receipt influenza vaccine 01/Mar/2008 start study previous adverse event associate use antiviral medication expect unable take zanamivir 72 hour study period plan spend 2 consecutive week outside Canada 100 km study site study period pregnant , plan become pregnant , study period breastfeeding , plan breastfeed , child 12 month age study period receipt immunoglobulin within six month study entry immunocompromising condition therapy would expect reduce efficacy vaccination plan receive cytotoxic radiation therapy study period history cardiovascular pulmonary disease require hospital admission within past year history asthma chronic respiratory disease participate trial result receipt investigational medication period zanamivir may take ( 15/Nov/2008 30/Apr/2009 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>antiviral drug</keyword>
	<keyword>influenza vaccine</keyword>
</DOC>